Home  About us  Contact
 

Hemostatic Agent (hemostatic + agent)

Distribution by Scientific Domains
Medical Sciences92%

Kinds of Hemostatic Agent

  • topical hemostatic agent
    		•

    Selected Abstracts

    Hydrophilic Polymers with Potassium Salt and Microporous Polysaccharides for Use as Hemostatic Agents

    DERMATOLOGIC SURGERY, Issue 12 2007
    JULIA HO MD
    BACKGROUND Postoperative bleeding can lead to complications such as hematoma, infection, dehiscence, and an unscheduled office visit. Topical hemostatic agents can be used to aid in hemostasis. OBJECTIVE The objective is to familiarize physicians with topical hemostatic agents,hydrophilic polymers with potassium salts (Urgent QR powder) and microporous polysaccharide hemispheres (Bleed-X). METHODS Two hemostatic agents, microporous polysaccharide hemospheres and hydrophilic polymers with potassium salt, are discussed. The literature is reviewed. RESULTS Numerous types of hemostatic agents exist. Topical hemostatic agents are safe, cost-effective, and efficient. CONCLUSION Microporous polysaccharide hemospheres and hydrophilic polymers with potassium salts can be an adjunct to hemostasis after cautery and ligation. Patients can apply hemostatic agents if they experience any bleeding leading to decreased office visits. Hemostatic agents used intraoperatively shorten bleeding time and enable the physician to use less cautery. Using hemostatic agents can lead to fewer hematomas, infections, and office visits. [source]

    Oxycellulose: Significant characteristics in relation to its pharmaceutical and medical applications

    ADVANCES IN POLYMER TECHNOLOGY, Issue 3 2009
    Bajerová Martina
    Abstract As a biomaterial, cellulose can be converted into a wide range of derivatives with desired properties for a variety of medical, biomedical, and pharmaceutical applications. The oxidation of cellulose yields oxidized cellulose (OC, oxycellulose, 6-carboxycellulose). OC represents an important class of biocompatible and bioresorbable polymers. In vivo bioabsorption of OC occurs via chemical depolymerization and enzymatic hydrolysis. Despite the fact OC is well established as a hemostatic agent and is widely used in a clinical practice, it still attracts a great interest and its new applications, especially pharmaceutical, are investigated. The present review is focused on characterization of OC's physical and chemical properties. Its synthesis and mechanisms involved in its in vivo and in vitro biodegradation are discussed. Medical and biomedical applications of OC are summarized, and especially its hemostatic, enterosorbent, and wound-healing properties are described. In addition to these applications, OC could be used as a pharmaceutical excipient in solid (e.g., tablets, microparticles), semisolid (e.g., gels), as well as liquid (e.g., suspensions) dosage forms. © 2009 Wiley Periodicals, Inc. Adv Polym Techn 28:199,208, 2009; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/adv.20161 [source]

    Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force

    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 4 2005
    U. MARTINOWITZ
    Summary.,Background:,Recombinant activated factor VII (rFVIIa) has been approved by the U.S. Food and Drug Administration (FDA) for almost a decade for hemophilic patients with inhibitors. Its off-label use as a hemostatic agent in massive bleeding caused by a wide array of clinical scenarios is rapidly expanding. While evidence-based guidelines exist for rFVIIa treatment in hemophilia, none are available for its off-label use. Objectives:,The aim of this study is to develop expert recommendations for the use of rFVIIa in patients suffering from uncontrolled bleeding (with special emphasis on trauma) until randomized, controlled trials allow for the introduction of more established evidence-based guidelines. Methods:,A multidisciplinary task force comprising representatives of the relevant National Medical Associations, experts from the Medical Corps of the Army, Ministry of Health and the Israel National Trauma Advisory Board was established in Israel. Recommendations were construed based on the analysis of the first 36 multi-trauma patients accumulated in the prospective national registry of the use of rFVIIa in trauma, and an extensive literature search consisting of published and prepublished controlled animal trials, case reports and series. The final consensus guidelines, together with the data of the first 36 trauma patients treated in Israel, are presented in this article. Results:,Results of the first 36 trauma patients: The prolonged clotting assays [prothrombin time (PT) and partial thromboplastin time (PTT)] shortened significantly within minutes following administration of rFVIIa. Cessation of bleeding was achieved in 26 of 36 (72%) patients. Acidosis diminished the hemostatic effect of the drug, while hypothermia did not affect it. The survival rate of 61% (22/36) seems to be favorable compared with published series of similar, or less severe, trauma patients (range 30%,57%). Conclusions:,As a result of the lack of controlled trials, our guidelines should be considered as suggestive rather than conclusive. However, they provide a valuable tool for physicians using rFVIIa for the expanding off-label clinical uses. [source]

    Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease

    PEDIATRIC ANESTHESIA, Issue 3 2005
    YARON RAZON MD
    Summary Background :,Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients. Methods :,The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration. Results :,In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg,1·h,1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted. Conclusions :,These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. [source]

    The use of desmopressin as a hemostatic agent: A concise review

    AMERICAN JOURNAL OF HEMATOLOGY, Issue 8 2007
    Massimo Franchini
    Desmopressin, a synthetic derivative of the antidiuretic hormone vasopressin, is the treatment of choice for most patients with von Willebrand disease and mild hemophilia A. Moreover, the compound has been shown to be useful in a variety of inherited and acquired hemorrhagic conditions, including some congenital platelet function defects, chronic liver disease, uremia, and hemostatic defects induced by the therapeutic use of antithrombotic drugs such as aspirin and ticlopidine. Finally, desmopressin has been used as a blood saving agent in patients undergoing operations characterized by large blood loss and transfusion requirements, but studies suggest that this is not as effective as other methods. This review briefly summarizes the current clinical indications on the use of desmopressin as a hemostatic agent. Am. J. Hematol., 2007. © 2007 Wiley-Liss, Inc. [source]

    Effects of Tisseel and FloSeal on Primary Ischemic Time in a Rat Fasciocutaneous Free Flap Model,

    THE LARYNGOSCOPE, Issue 2 2004
    Aaron W. Partsafas BS
    Abstract Objectives: Free flaps are the technique of choice for reconstruction of defects resulting from extirpation of tumors of the head and neck. Advances in microsurgical technique have resulted in success rates of greater than 95%. Numerous intraoperative factors, ranging from technical issues to topically applied agents, can complicate the outcome of microsurgical free tissue transfer. Synthetic tissue adhesives and hemostatic agents are playing an ever-increasing role in reconstructive surgery. The safety of these factors in free flap surgery has not been ascertained. Study Design: Animal Care Committee live rat model. Methods: Male Sprague-Dawley rats were divided into three groups: group I, Control; group 2, FloSeal; group 3, Tisseel. In each group, a 3 × 6 cm ventral fasciocutaneous groin flap based on the left superficial epigastric artery was elevated and the experimental material applied beneath the flap and around the flap pedicle prior to suturing of the flap back to the wound bed. The experimental materials consisted of 0.2 mL saline in the control group, 0.5 mL FloSeal, and 0.2 mL Tisseel. In phase I of this study, the effect of each treatment on flap survival was assessed by survival at postoperative day 4. In phase II of the study, the effects of these agents on ischemic tolerance was investigated. Five rats in each treatment group were exposed to ischemic times of 6, 8, 10, and 12 hours. Survival of the flap was assessed 7 days after reversal of the ischemia. Probit curves and the critical ischemic time (CIT50) were calculated. Results: All flaps survived the 2-hour period of ischemia and were viable at postoperative day 4. Flap survival from group 1 (Control), group 2 (FloSeal), and group 3 (Tisseel) at the various ischemic times was as follows: at 6 hours, 80%, 80%, and 80%, respectively; at 8 hours, 80%, 80%, 60%; at 10 hours, 60%, 33%, 40%; at 12 hours, 20%, 20%, 0%. The CIT50 for the Control, FloSeal, and Tisseel groups was 9.4, 9.0, and 7.0 hours, respectively. Conclusions: FloSeal, a thrombin-based hemostatic agent, and Tisseel, a fibrin glue, displayed no adverse effect on flap survival in this model. [source]

    Antibacterial Properties of an Iron-based Hemostatic Agent In Vitro and in a Rat Wound Model

    ACADEMIC EMERGENCY MEDICINE, Issue 7 2009
    David O. Bracho
    Abstract Objectives:, Topical hemostatic agents are currently employed on the battlefield for control of major hemorrhage and have potential for use in civilian settings. Some of these compounds may also be antibacterial. Given the behavior of these compounds, the purpose of this study was to assess the potential antibacterial properties of an iron oxyacid,based topical hemostatic agent against three problematic species of wound-contaminating microorganisms: Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, and methicillin-resistant Staphylococcus epidermidis. Methods:, Bacteria were treated in vitro with the test powder for 30 minutes and then assessed for viability. Long-term (8-hour) inhibition of bacterial growth was also examined. In vivo, a rat full-thickness 1-cm2 skin wound was studied. Wounds were contaminated, treated, and then quantitatively cultured 24 hours later. Results:, The lethal dose for 99% of the organisms (LD99) for the compound against each organism ranged from 0.89 (±0.28) to 4.77 (±0.66) mg/mL (p < 0.05). The compound produced sustained inhibition over 8 hours at both 1 and 5 mg/mL (p < 0.05 for each), for P. aeruginosa, S. epidermidis, and S. aureus. In vivo, activity was noted against only P. aeruginosa, with the largest magnitude reduction being on the order of 3-log colony-forming units (CFU; p < 0.01). Conclusions:, The iron-based agent studied possesses significant in vitro and lesser in vivo antibacterial effects. Further optimization of the delivery, dosing, and evaluation of this agent in a larger animal model with more humanlike skin structures may reveal important wound effects beyond control of bleeding. [source]

    Hydrophilic Polymers with Potassium Salt and Microporous Polysaccharides for Use as Hemostatic Agents

    DERMATOLOGIC SURGERY, Issue 12 2007
    JULIA HO MD
    BACKGROUND Postoperative bleeding can lead to complications such as hematoma, infection, dehiscence, and an unscheduled office visit. Topical hemostatic agents can be used to aid in hemostasis. OBJECTIVE The objective is to familiarize physicians with topical hemostatic agents,hydrophilic polymers with potassium salts (Urgent QR powder) and microporous polysaccharide hemispheres (Bleed-X). METHODS Two hemostatic agents, microporous polysaccharide hemospheres and hydrophilic polymers with potassium salt, are discussed. The literature is reviewed. RESULTS Numerous types of hemostatic agents exist. Topical hemostatic agents are safe, cost-effective, and efficient. CONCLUSION Microporous polysaccharide hemospheres and hydrophilic polymers with potassium salts can be an adjunct to hemostasis after cautery and ligation. Patients can apply hemostatic agents if they experience any bleeding leading to decreased office visits. Hemostatic agents used intraoperatively shorten bleeding time and enable the physician to use less cautery. Using hemostatic agents can lead to fewer hematomas, infections, and office visits. [source]

    Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients,

    AMERICAN JOURNAL OF HEMATOLOGY, Issue 3 2010
    Carrie A. Thompson
    Systemic light-chain (AL) amyloidosis may be associated with acquired factor X (FX) deficiency and optimal management of this coagulopathy is unknown. We reviewed our experience with 60 patients with isolated FX deficiency (,50%) due to AL amyloidosis that underwent an invasive procedure between 1975 and 2007. They were classified as having severe (<10%; n = 6), moderate (10,25%; n = 15), or mild (26,50%; n = 39) FX deficiency. The patients underwent a total of 112 procedures, 19 (17%) of which were managed with periprocedural treatment with one or more hemostatic agents. There were complications in 14 (13%) procedures (bleeding = 12, thrombosis = 1, death = 1). Baseline FX level was not predictive of bleeding risk; the only association with postintervention bleeding was central venous catheter placement. However, bleeding complications were relatively infrequent, particularly in patients with mild or moderate FX deficiency undergoing nonvascular procedures. Activated recombinant factor VII might be considered in patients undergoing major surgical procedures, but further experience is needed. Optimal management of AL patients with FX deficiency undergoing invasive procedures remains to be determined. Am. J. Hematol., 2010. © 2009 Wiley-Liss, Inc. [source]

    Effects of Tisseel and FloSeal on Primary Ischemic Time in a Rat Fasciocutaneous Free Flap Model,

    THE LARYNGOSCOPE, Issue 2 2004
    Aaron W. Partsafas BS
    Abstract Objectives: Free flaps are the technique of choice for reconstruction of defects resulting from extirpation of tumors of the head and neck. Advances in microsurgical technique have resulted in success rates of greater than 95%. Numerous intraoperative factors, ranging from technical issues to topically applied agents, can complicate the outcome of microsurgical free tissue transfer. Synthetic tissue adhesives and hemostatic agents are playing an ever-increasing role in reconstructive surgery. The safety of these factors in free flap surgery has not been ascertained. Study Design: Animal Care Committee live rat model. Methods: Male Sprague-Dawley rats were divided into three groups: group I, Control; group 2, FloSeal; group 3, Tisseel. In each group, a 3 × 6 cm ventral fasciocutaneous groin flap based on the left superficial epigastric artery was elevated and the experimental material applied beneath the flap and around the flap pedicle prior to suturing of the flap back to the wound bed. The experimental materials consisted of 0.2 mL saline in the control group, 0.5 mL FloSeal, and 0.2 mL Tisseel. In phase I of this study, the effect of each treatment on flap survival was assessed by survival at postoperative day 4. In phase II of the study, the effects of these agents on ischemic tolerance was investigated. Five rats in each treatment group were exposed to ischemic times of 6, 8, 10, and 12 hours. Survival of the flap was assessed 7 days after reversal of the ischemia. Probit curves and the critical ischemic time (CIT50) were calculated. Results: All flaps survived the 2-hour period of ischemia and were viable at postoperative day 4. Flap survival from group 1 (Control), group 2 (FloSeal), and group 3 (Tisseel) at the various ischemic times was as follows: at 6 hours, 80%, 80%, and 80%, respectively; at 8 hours, 80%, 80%, 60%; at 10 hours, 60%, 33%, 40%; at 12 hours, 20%, 20%, 0%. The CIT50 for the Control, FloSeal, and Tisseel groups was 9.4, 9.0, and 7.0 hours, respectively. Conclusions: FloSeal, a thrombin-based hemostatic agent, and Tisseel, a fibrin glue, displayed no adverse effect on flap survival in this model. [source]

    Antibacterial Properties of an Iron-based Hemostatic Agent In Vitro and in a Rat Wound Model

    ACADEMIC EMERGENCY MEDICINE, Issue 7 2009
    David O. Bracho
    Abstract Objectives:, Topical hemostatic agents are currently employed on the battlefield for control of major hemorrhage and have potential for use in civilian settings. Some of these compounds may also be antibacterial. Given the behavior of these compounds, the purpose of this study was to assess the potential antibacterial properties of an iron oxyacid,based topical hemostatic agent against three problematic species of wound-contaminating microorganisms: Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, and methicillin-resistant Staphylococcus epidermidis. Methods:, Bacteria were treated in vitro with the test powder for 30 minutes and then assessed for viability. Long-term (8-hour) inhibition of bacterial growth was also examined. In vivo, a rat full-thickness 1-cm2 skin wound was studied. Wounds were contaminated, treated, and then quantitatively cultured 24 hours later. Results:, The lethal dose for 99% of the organisms (LD99) for the compound against each organism ranged from 0.89 (±0.28) to 4.77 (±0.66) mg/mL (p < 0.05). The compound produced sustained inhibition over 8 hours at both 1 and 5 mg/mL (p < 0.05 for each), for P. aeruginosa, S. epidermidis, and S. aureus. In vivo, activity was noted against only P. aeruginosa, with the largest magnitude reduction being on the order of 3-log colony-forming units (CFU; p < 0.01). Conclusions:, The iron-based agent studied possesses significant in vitro and lesser in vivo antibacterial effects. Further optimization of the delivery, dosing, and evaluation of this agent in a larger animal model with more humanlike skin structures may reveal important wound effects beyond control of bleeding. [source]